| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4-Ethylresorcinol targets tyrosinase, serving as a substrate for the enzyme. It also targets tyrosinase-related protein (TRP)-2, attenuating its mRNA and protein expression. The compound has antioxidant effects by inhibiting lipid peroxidation. It also has inhibitory activity against acetylcholinesterase.
|
|---|---|
| ln Vitro |
4-Ethylresorcinol demonstrates in vitro hypopigmentary effects. It attenuates mRNA and protein expression of TRP-2. The compound has antioxidant effects by inhibiting lipid peroxidation. It also has inhibitory activity against tyrosinase and acetylcholinesterase.
|
| ln Vivo |
In vivo activity data for 4-Ethylresorcinol are not extensively documented. Its hypopigmentary effects suggest potential in vivo efficacy for skin lightening. Its antioxidant effects suggest potential in vivo protective effects. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for 4-Ethylresorcinol involves measuring its interaction with tyrosinase. As a substrate for tyrosinase, 4-Ethylresorcinol is oxidized by the enzyme. The assay typically monitors the oxidation of 4-Ethylresorcinol spectrophotometrically. Its inhibitory activity against acetylcholinesterase can be assessed using standard enzyme assays.
|
| Cell Assay |
In vitro cellular assays for 4-Ethylresorcinol typically use B16 melanoma cells to assess its hypopigmentary effects. Cells are treated with the compound at various concentrations. Melanin content is measured spectrophotometrically. The expression of TRP-2 is analyzed by Western blot or qPCR. Antioxidant activity can be assessed by measuring lipid peroxidation.
|
| Animal Protocol |
In vivo animal experiments for 4-Ethylresorcinol are not extensively documented. As a compound with hypopigmentary effects, standard in vivo studies would involve animal models of hyperpigmentation. The compound would be administered via topical or oral routes. Melanin content in skin and histopathological analysis would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-Ethylresorcinol are not extensively documented. As a small molecule, the compound is expected to have reasonable bioavailability. Its resorcinol structure may influence its absorption, distribution, metabolism, and excretion. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4-Ethylresorcinol are not extensively available. As a resorcinol derivative, it is generally considered to have a favorable safety profile. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
4-Ethylresorcinol is a type of resorcinol compound.
4-Ethylresorcinol is a resorcinol derivative that acts as a substrate for tyrosinase and possesses hypopigmentary effects. It attenuates TRP-2 expression and has antioxidant effects by inhibiting lipid peroxidation. The compound also inhibits acetylcholinesterase. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C8H10O2
|
|---|---|
| Molecular Weight |
138.17
|
| Exact Mass |
138.068
|
| CAS # |
2896-60-8
|
| PubChem CID |
17927
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
273.8±10.0 °C at 760 mmHg
|
| Melting Point |
95-98 °C(lit.)
|
| Flash Point |
134.4±13.6 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.579
|
| LogP |
1.75
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
103
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC1=C(C=C(C=C1)O)O
|
| InChi Key |
VGMJYYDKPUPTID-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H10O2/c1-2-6-3-4-7(9)5-8(6)10/h3-5,9-10H,2H2,1H3
|
| Chemical Name |
4-ethylbenzene-1,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (723.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2375 mL | 36.1873 mL | 72.3746 mL | |
| 5 mM | 1.4475 mL | 7.2375 mL | 14.4749 mL | |
| 10 mM | 0.7237 mL | 3.6187 mL | 7.2375 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
